The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.

Aesthet Surg J · 2021 · PMC8598194 · PMID 33944905

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

In both studies, among study completers, there was a slight trend towards longer retreatment periods.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.